US 12,290,526 B2
Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses
Patricia Del Carmen Garcia Armenta, Jalisco (MX)
Assigned to Federico Amezcua Amezcua, Jalisco (MX); and Carlos Amezcua Amezcua, Jalisco (MX)
Appl. No. 17/267,239
Filed by Federico Amezcua Amezcua, Jalisco (MX); and Carlos Amezcua Amezcua, Jalisco (MX)
PCT Filed Aug. 13, 2019, PCT No. PCT/MX2019/000091
§ 371(c)(1), (2) Date Feb. 9, 2021,
PCT Pub. No. WO2020/036478, PCT Pub. Date Feb. 20, 2020.
Claims priority of application No. A/2018/009812 (MX), filed on Aug. 13, 2018.
Prior Publication US 2021/0228598 A1, Jul. 29, 2021
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 31/216 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/573 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/216 (2013.01); A61P 29/00 (2018.01)] 2 Claims
 
1. A pharmaceutical composition consisting of a synergic combination of:
i. aceclofenac in basic form,
ii. betamethasone in a phosphate or a dipropionate salt, and
iii. a pharmaceutically acceptable vehicle and/or excipient,
wherein the aceclofenac in basic form is present in the composition in an amount that is 15 times greater than the amount of the betamethasone in phosphate or dipropionate salt;
wherein the composition is formulated as a topical gel or cream.